Early Visual Outcomes Of A New Enhanced Monofocal Intraocular Lens

To evaluate early visual outcomes, safety and efficacy of a new enhanced monofocal intraocular lens over 3 months.  

Nethradhama Super Speciality Eye hospital, Bangalore, India.  

This is a prospective, single center, interventional study, in which Vivinex Impress XY1-EM (Hoya Surgical Optics, Singapore) was implanted in 40 eyes. Post operatively on day 15- and 3-months following tests were done: Uncorrected (UDVA) and corrected distance visual acuity (CDVA), manifest sphere, cylinder and Spherical Equivalent (SE), Contrast sensitivity testing (FACT), internal and total aberrations assessment using ray tracing aberrometry, objective scatter index, dilated examination for IOL position, binocular corrected defocus curve using defocusing lenses from +3 to –3D and reading speed using Salzburg reading desk (SRD) at preferred reading and intermediate distance. 

40 eyes of 30 patients, of which 19 were males and 11 were females with mean age of 64.9+/-10.2 years were evaluated post operatively on 15 days and 3 months. UDVA was 0 LogMAR in 95% of patients at 3 months with 100% of patients showing 0.2 LogMAR. Mean UIVA at 66cm was 0.18+/-0.11 LogMAR. Mean SRD reading speed was 170.3+/-66.6 words per minute. The defocus curve showed stable visual acuity and smoother curve between –2D and +2D. OSI at 15 days post operatively was 3.11+/-1.23 which improved to 1.68+/-0.98 at 3 months. Mean internal spherical aberrations at the end of 3 months was 0.022+/-0.159. At 3 months, 98% showed spectacle independence for distance and 92% were spectacle independent for intermediate vision with no dysphotopsias.

Early visual outcomes of Hoya Vivinex Impress XY1-EM were found to be safe and effective with a good balance between spectacle independence and quality of vision.